Relatlimab

Relatlimab is a monoclonal antibody designed for the treatment of melanoma.

[2][5] It is made using Chinese hamster ovary cells.

[2] As of 2018[update], relatlimab is undergoing Phase II/III trials.

[6] The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.

[2][5] Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).